Mytomorrows and omeros corporation collaborate to provide an expanded access program for narsoplimab

Amsterdam & seattle--(business wire)--mytomorrows, a global health technology company, and omeros corporation (nasdaq: omer), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics, today announced a collaboration. the collaboration broadens omeros’ expanded access program to support availability of omeros’ novel investigational complement inhibitor narsoplimab in several countries around the world. narsoplimab is
OMER Ratings Summary
OMER Quant Ranking